2014
Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases 2014, 1: ofu073. PMID: 25734143, PMCID: PMC4281792, DOI: 10.1093/ofid/ofu073.Peer-Reviewed Original ResearchDrug-resistant TBTreatment of tuberculosisNew drug regimenTransmission fitnessDrug regimensDrug regimenTreatment successDrug-susceptible TBAppropriate second-line therapyDR-TB prevalenceSecond-line therapyDrug resistance trendsTreatment success rateHigher treatment successNovel drug regimensEmergence of resistancePopulation-level dataTB regimensShort-term surveillanceDS-TBNew regimenClinical trialsEarly diagnosisRegimensDrug resistance
2012
The impact of new tuberculosis diagnostics on transmission: why context matters
Lin HH, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bulletin Of The World Health Organization 2012, 90: 739-747. PMID: 23109741, PMCID: PMC3471051, DOI: 10.2471/blt.11.101436.Peer-Reviewed Original ResearchConceptsNew tuberculosis diagnosticsNew diagnostic toolsPatient lossHuman immunodeficiency virus (HIV) infectionTuberculosis diagnosticsSmear-negative pulmonary tuberculosisDiagnostic toolImmunodeficiency virus infectionTreatment success rateSmear-negative casesIncidence of tuberculosisEpidemiology of tuberculosisPatient defaultPulmonary tuberculosisTuberculosis careDiagnostic pathwayTuberculosis transmissionSymptomatic individualsVirus infectionSmear microscopyTuberculosisAnnual declineDiagnosisAbsolute changeSuccess rate